Kornimate/medical-research-clean huggingface dataset:
benefits of trimetazidine in masld patients

Conditions: Metabolic Associated Fatty Liver Disease

Summary: objective of this study is to determine the clinical benefits of trimetazidine in improvement of masld

the study will evaluate the possible benefits of trimetazidine when added to pateints with metabolic associated fatty liver disease

Eligibility criteria:
inclusion criteria: participants were included if they met masld diagnostic criteria, which required imaging-confirmed hepatic steatosis (via abdominal ultrasound and cap), along with metabolic factors (bmi ≥25 kg/m², diabetes/dysglycemia, blood pressure ≥130/85 mmhg, triglycerides ≥150 mg/dl, or reduced hdl-cholesterol) exclusion criteria: the study excluded those with * alternative steatosis causes (alcohol intake \>50 g/day women or \>60 g/day men * drug-induced injury, hepatitis c, wilson disease). * additional exclusion criteria covered ages below 18 years, pregnancy. decompensated cirrhosis, portal hypertension, hepatocellular carcinomas. * trimetazidine contraindications (parkinson's disease, parkinsonian symptoms, tremors, severe renal impairment), patients on statins, sodium glucose transporter 2 inhibitors (sglt2), glucagon-like peptide 1(glp1) were among the other exclusion criteria

Keywords: trimetazidine in masld
neuroendocrine mechanisms in adiposity: an integrated approach to the characterization of potential pharmacological novel targets based on experimental and clinical models

Conditions: Endocrine Disorders; Adiposity; Pituitary Adenoma; Cushing Syndrome; Acromegaly; Hypopituitarism

Summary: the goal of this observational study is to evaluate, retrospectively and prospectively, the effect of different hormonal and neuropeptide dysfunctions on the body composition of patients suffering from hypothalamic-pituitary pathologies, and to evaluate the potential beneficial effect of surgical and medical treatments with agonists and antagonists of hypothalamic neuropeptides, currently available, on the development and treatment of adiposity and negative cross-talk between adiposity and muscle/bone tissue


Eligibility criteria:
inclusion criteria: obese patients affected and not by hypothalamic-pituitary diseases exclusion criteria: 1. minor subjects; 2. pregnant and/or breastfeeding women; 3. patients suffering from states of primary and/or acquired immunodeficiencies, and/or serious impairment of general clinical conditions (e.g. metastatic neoplasms; immunosuppressive therapies; worsening/reacerbated/compensated chronic pathologies); 4. patients unable to understand and sign the informed consent.
sodium creatine phosphate in heart valve surgery

Conditions: Heart Valve Diseases

Summary: to explore the effect of intraoperative sodium creatine phosphate on myocardial protection in patients undergoing valve surgery

objective: to explore the effect of intraoperative sodium creatine phosphate on myocardial protection in patients undergoing valve surgery methods: 250 patients undergoing valve surgery were randomly divided into experimental group and control group. 5g creatine phosphate was dissolved in 50ml saline solution. after induction of anesthesia, the patients were first given a load dose of 1g, 20min (30ml / h) , and then pumped at a rate of 1 g / h (10 ml / h). the control group was treated with saline in the same manner. the ctni level was measured at the corresponding time points. hemodynamic indexes and postoperative complications were recorded.

Eligibility criteria:
inclusion criteria: * valvular disease patients requiring valvular replacement or repair surgery with cardiopulmonary bypass(cpb) exclusion criteria: * thoracoscopic valve surgery * other organ dysfunction: such as cancer, organ failure, severe anemia, infection * patients with mental disorders * coagulopathy, active ulcer, ischemic or hemorrhagic stroke (within 6 months), trauma
motor slowing and its lesion-related correlates in alzheimer's disease

Conditions: Alzheimer Disease

Summary: in ad (alzheimer disease), the anatomic correlates of attention disorders (as evaluated by motor slowing) have not been thoroughly characterized.


Eligibility criteria:
inclusion criteria: * patients * age between 40 and 85 * french mother tongue * consulting at the amiens memory resource and research centre (cmrr) for: * mci, according to albert et al.'s criteria (albert et al., 2011) * mild dementia (mmse\>20) due to ad, according to mckhann's criteria (mckhann et al., 2011). * mild dementia due to lbd, according to mckeith et al.'s criteria (mckeith et al., 2005). * mild dementia due to ftld, according to rascovsky et al.'s criteria (rascovsky et al., 2011). * social security coverage * healthy controls * healthy age and gender matched volunteers will be recruited into the study from the general population. exclusion criteria: * reading or writing difficulties related to a learning disorder or illiteracy. * a medical history with a potentially significant impact on cognition (non-corrected thyroid disorders or heart failure): * nyha stage iv dyspnoea. * respiratory impairment requiring oxygen therapy. * liver impairment. * kidney failure, progressing neoplastic disease, or past or present alcohol abuse. * past or present neurological disorders other than those having prompted consultation in the memory clinic: * stroke. * meningitis or encephalitis. * severe head injury. * sensorimotor impairments (sensory, proprioceptive, cerebellar and visual impairments). * epilepsy (requiring ongoing treatment), * psychiatric disorders (other than treated depression). * treatment with psychotropic medications (other than anxiolytics or antidepressant withdrawn or initiated in the previous month). patients with parkinsonian syndrome were examined in the "on-drug" state. * impossibility to perform a neuropsychological evaluation or brain mri. * withdrawal from the study at any time, if desired. * pregnancy * contra-indication to mri: * nerve stimulators * cochlear implants * ferromagnetic foreign bodies close to nervous structures in the eye or brain * cerebral shunts * dental appliances * legal guardianship or incarceration.

Keywords: motor slowing
outcomes and predictors of mortality among preterm infants with neonatal sepsis

Conditions: Neonatal Sepsis

Summary: a prospective cross-sectional study of outcomes and predictors of mortality among preterm infants with neonatal sepsis admitted in nicu of assiut university children's hospital

neonatal sepsis is a clinical syndrome of bacteremia with systemic signs and symptoms of infection in the first 28 days of life. it can also result from viral and fungal invasions of the bloodstream it is one of the events that can occur during neonatal intensive care unit (nicu) admission. it contributes significantly to the morbidity of very preterm (vp: \<32 weeks gestational age) and/or very low birthweight (vlbw: \<1500 g) infants sepsis is a major cause of neonatal mortality and neurodevelopmental impairment among neonates which results in death and major disability for 39% of those affected even with timely antibiotic treatment . globally, it is estimated that more than 1.4 million neonatal deaths annually are the consequence of invasive infections . infection-specific mortality varies by geographic region and neonatal risk factors like gestational age and body weight . it contributes to nearly 30-50% of neonatal deaths in developing countries . the risk of death is highest in the first 24 h of life when more than half of deaths occur and about three-quarters of all neonatal deaths occur within the first week of life.

Eligibility criteria:
inclusion criteria: * all preterm infants (\<37 weeks) diagnosed with neonatal sepsis * preterm infants aged 0-28 days exclusion criteria: * full term infants (\> 37 weeks gestation) -neonates with congenital anomalies -neonates diagnosed with metabolic diseases * neonates with birth asphyxia
diastolic exercise stress testing in heart failure

Conditions: Heart Failure With Preserved Ejection Fraction

Summary: patients with an intermediate risk (hfa-peff score 2-4 points) for heart failure with preserved ejection fraction (hfpef) will be further investigated with invasive right heart catheterization. all patients with a resting pulmonary artery wedge pressure (pawp) \ 25mmhg.

patients reporting to the investigators' clinic for in- and outpatient consultation and a hfa-peff score of 2-4 points will be recruited if their dyspnea is not sufficiently explained by other causes than hfpef. patients will undergo a baseline clinical exam, transthoracic echocardiography with measurement of diastolic parameters, and ecg. nyha class will be reported, standard lab works (ntprobnp, gfr, crp, hb, plt, blood gas analysis) will be taken. the number of patients with a pawp increase in right heart catheterization (brachial access under sonographic guidance) from a resting value of \ 25mmhg during stress testing will be assessed across the four interventions. during bicycle ergometry (semi-supine position) spiroergometric data and gas exchange variables (cardiopulmonary exercise testing) will be co-assessed. between the testing modalities a 10-minute break will allow hemodynamic variables to normalize.

Eligibility criteria:
inclusion criteria: * age \> 18 years * unclear etiology of dyspnea with non-invasive testing * hfa-peff score 2-4 points and thus an intermediate risk for hfpef * willingness to participate and obtained written consent exclusion criteria: * consent for study participation not obtained * age \< 18 years * medical contraindications to perform right heart catheterization

Keywords: diastolic stress testing hfpef
a study to assess the effect of high fat meal and increased gastric ph on the bioavailability of an extended release formulation of bms-663068 in healthy subjects

Conditions: Infection, Human Immunodeficiency Virus

Summary: the purpose of this study is to estimate the effect of high fat meal and increased gastric ph on bms-663068 bioavailability


Eligibility criteria:
inclusion criteria: 1. signed informed consent 2. target population: healthy males and females. 3. males and females 4. women of child bearing potential (wocbp) with negative serum or urine pregnancy test 5. women must not be breastfeeding 6. men and wocbp must agree to follow instructions for contraception exclusion criteria: 1. history of any chronic or acute illness or gastrointestinal disease 2. any major surgery within 4 weeks of study drug administration 3. evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ecg or clinical laboratory determinations beyond what is consistent with the target population. 4. history of allergy to hiv attachment inhibitors, famotidine or high fat meal 5. history of smoking
recovery time in thai patients with upper or lower respiratory tract infections treated with klacid mr

Conditions: Respiratory Tract Infection

Summary: the investigators hypothesize that klacid modified release (mr) shortens symptom recovery time in thai patients with upper or lower respiratory tract infections.


Eligibility criteria:
inclusion criteria: * patients with upper or lower respiratory tract infection. * patient is male or female ≥ 18 years of age. exclusion criteria: * known hypersensitivity to or previously intolerant of macrolides. * illness severe enough to warrant hospitalization or parenteral therapy. * concomitant use of any of the following medications: * drugs metabolized by cyp3a isozyme: alprazolam, astemizole, carbamazepine, cilostazol, cisapride, cyclosporin, disopyramide, ergot alkaloids, lovastatin, methylprednisolone, midazolam, omeprazole, oral anticoagulants (e.g. warfarin), pimozide, quinidine, rifabutin, sildenafil, simvastatin, tacrolimus, terfenadine, triazolam and vinblastine. * drugs metabolized by other isozymes within cyp450 system: phenytoin, theophylline and valproate. * colchicine * digoxin * some antiretrovirals: zidovudine and ritonavir. * severe immunodeficiency and chronic disease conditions. * renal or hepatic impairment.

Keywords: post-marketing observational study upper or lower respiratory tract infection klacid mr
effects of a bakery product enriched with fibre and l-carnitine on insulin resistance in patients with metabolic syndrome

Conditions: Metabolic X Syndrome; Overweight; Dyslipidemias

Summary: the aim of this study was to evaluate the efficacy of a bakery product enriched with dietary fibre and l-carnitine on glucose homeostasis and insulin sensitivity in overweight patients with or without metabolic syndrome.

conceivably, different biochemical changes in insulin-mediated signalling pathways may contribute to an impaired insulin-mediated glucose transport and metabolism that eventually results in insulin resistance and the clinical features of metabolic syndrome. according to this, both compounds -l-carnitine and dietary fiber- interacting by different mechanism of action could improve glucose homeostasis and insulin sensitivity. however, the health beneficial effects of the combination of both compounds are not shown and confirmation of the functionality of such products must be accomplished by conducting the appropriate studies intervention nutrition.

Eligibility criteria:
inclusion criteria: * bmi between 25 and 35 kg/m2 exclusion criteria: * pregnancy or lactation * kidney, liver and thyroid disease * history of cardiovascular or chronic inflammatory disease * diabetes mellitus * lipid-lowering medication * triglyceride concentration \> 400 mg/dl * consumption of other carnitine and/or fibre-enriched foods

Keywords: l-carnitine fibre bakery product insulin resistance
effect of a synergistic food basket on metabolic syndrome risk

Conditions: Metabolic Syndrome; Insulin Resistance

Summary: the study evaluates the effect of a diet combining two different functional concepts on markers associated to cardiometabolic risk. the functional concepts are selected on the basis of their reported ability to influence the inflammatory tonus. it is hypothesized that the medium-term consumption of a diet combining low gi-prebiotic foods may positively influence various biomarkers associated with the risk for developing metabolic syndrome and cardiometabolic disease. also, the combination of functional mechanisms are expected to result in synergistic effects.

the intervention is carried out in healthy women following a randomized crossover design in which an "active" (functional") diet is compared with a control diet formulated in agreement with the nordic dietary recommendations but lacking the functional ingredients of the active regime. the active diet supplies important daily amounts of dried legumes and wholegrain cereal products. each dietary treatment is applied for 4 weeks separated by a 4-6 week washout period. subjects are encouraged to maintain a stable body weight under the whole trial.

Eligibility criteria:
inclusion criteria: * bmi between 25 and 32 kg/m2 exclusion criteria: * fasting blood glucose \> 6.1 mmol/l * medication for high blood pressure and/or elevated blood cholesterol

Keywords: cardiometabolic risk metabolic syndrome prebiotics legumes wholegrain cereal functional diet low glycemic index diet
biosafety of musical instruments in the icu

Conditions: Nosocomial Infection

Summary: this study investigates the efficacy of the institutional disinfection protocol for musical instruments in the icu of the music therapy service of the university hospital fundación santa fe de bogotá (fsfb), colombia.

introduction: nosocomial infections can negatively affect the recovery and well-being of patients. music therapy is a profession that uses music and sounds to improve the health, well-being and quality of life of patients. musical instruments are regularly used in music therapy sessions, such as the string or percussion instruments, among others. since the musical instruments are also played and handled by the patients, the question arises if the disinfection and cleaning protocol for musical instruments of the music therapy service at the university hospital fundación santa fe de bogotá (fsfb) is effective and safe. objectives: to establish the effectiveness and impact of the disinfection protocol of musical instruments used by the music therapy service in the icus of the fsfb. methodology: this is a study carried out in 2 phases. the first phase corresponds to an experimental design in which the presence of microbiological viability will be evaluated through atp bioluminescence tests and cultures before and after the application of the disinfection and cleaning protocol in a controlled environment. the second phase corresponds to a prospective cohort study in which music therapy patients will be followed up ver a period of two months, determining the impact of the disinfection and cleaning protocol. analysis: a descriptive analysis will be applied where the qualitative variables will be presented in their absolute and relative frequencies. for the quantitative variables, the kolgomorov-smirnov test will be applied to define the distribution of the data and, according to these, corresponding descriptive statistics will be carried out. in addition, a bivariate analysis will be performed between the outcome variable (infection or not) versus the exposure variables with a regression-type confounding analysis (logistic - binary as applicable) to identify co-variability phenomena. expected results: this study seeks to improve patient safety, raise awareness in the music therapy community about the importance of proper cleaning of their work tools, and promote inter- and transdisciplinary knowledge between the fields of music therapy, critical medicine and epidemiology.

Eligibility criteria:
inclusion criteria: * being hospitalized in the and having participated in a music therapy service from july 1st to august 31st 2023. exclusion criteria: * not having participated in a music therapy service during the same time frame.

Keywords: music therapy biosafety musical instruments intensive care units
anti-mullerian hormone (amh) as marker of ovarian reserve

Conditions: Breast Cancer

Summary: this is a multicentre, prospective study willing to evaluate amh levels changes in response to chemotherapy plus gnrha. in the present study we propose to determine amh levels in breast cancer patients, aged \<40yrs receiving adjuvant chemotherapy and ovarian suppression by means of gnrha with the aim to assess the role of amh as surrogate marker of the preservation of ovarian reserve exerted by gnrha.

patients will receive 4 to 8 cycles of chemotherapy according to institutional guidelines. triptorelin 3.75 will be administered as an intramuscular injection before chemotherapy and every 28 days thereafter for all the duration of chemotherapy in patients with er negative tumors and for 2 to 5 years in patients with er positive tumors according to institutional guidelines. patients with er+ve tumour will receive tamoxifen for 5 years at the end of chemotherapy as standard care. a blood sample will be drawn after signed informed consent to determine baseline amh levels. a blood sample for determination of amh levels will be collected at the end of chemotherapy and at 12 months after the end of chemotherapy.

Eligibility criteria:
inclusion criteria: 1. female subjects, aged \<40yr at the time of breast cancer diagnosis 2. diagnosis of operable breast cancer any t and n, any er 3. patients candidate to adjuvant chemotherapy for 4-8 cycles. 4. patients compliant to adhere to all protocol procedures. 5. adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 28 days prior to the start of the study treatment. 6. negative pregnancy test at the study enrolment; fertile women must use effective contraception during chemotherapy 7. patients must be able to understand and sign written informed consent. - exclusion criteria: 1. presence of distant metastasis 2. clinically significant cardiovascular disease 3. psychological or social conditions which might affect study compliance 4. unstable neurologic function 5. patients with known allergy to any of the components of the study medication 6. pregnancy or lactation 7. any condition that, in the opinion of the physician is likely to affect inclusion of the subject into the study.
impact of bariatric surgery on the evolution of nonalcoholic fatty liver disease: a comparative clinical trial between sleeve gastrectomy and gastric bypass

Conditions: Obesity; Fatty Liver

Summary: aim: to compare prospectively two bariatric surgery techniques: sleeve gastrectomy (sg) vs gastric bypass (gb) in the evolution of nonalcoholic fatty liver disease (nafld) measured by the transient elastography in the first year. methods: this is a randomized clinical trial with morbidly obese patients, between 18-60 years old from a federal hospital, ministry of health, brazil. patients were divided into 2 groups: group 1 - sg (n = 30) and group 2 - gb (n = 30). the randomization was made by lots. in the gb the investigators created 30 ml pouch, with a pancreatic and an alimentary limb of 1 meter, and a calibrated gastroenterostomy (1.5 cm diameter). in sg the investigators calibrated the gastric tube with a bougie number 32 (70 ml). the variables were compared one week before surgery and in the postoperative time (1, 3, 6 and 12 months). the variables were: patient anthropometry, laboratory tests and the transient liver elastography.


Eligibility criteria:
inclusion criteria: the eligibility criteria was: * morbid obesity patient grade ii or grade iii (bmi \> 35) in prepare to bariatric surgery. exclusion criteria: the exclusion criteria were: * age under 18 years or greater than 65 years old, * chronic diseases (heart failure, chronic liver disease), and * alcohol abuse (abuse was considered in those who consume more than 14 drinks per week).

Keywords: bariatrics transient elastography
polyacrylate polyalcohol copolymer for vesicoureteral reflux

Conditions: Vesicoureteral Reflux (VUR); Urinary Tract Infection

Summary: endoscopic correction of vur has gained its popularity due to its less invasiveness, associated low morbidity and short hospital stay. although short term follow-up had justified their efficacy; however, long term recurrence and complications following endoscopic correction were also being reported in the literatures (6). currently, there are insufficient evidences on the efficacy and safety of biocompatible tissue augmenting materials used for endoscopic correction of vur; particularly on the new tissue bulking agents. (6) polyacrylate polyalcohol copolymer (ppc)-vantris ® (promedon, cordoba, argentina) is the newest tissue augmenting biocompatible acrylics used for endoscopic correction of vur.


Eligibility criteria:
inclusion criteria: * included patients for the study were only those who had 1- 3months and \>1year post-treatment follow-up study with voiding cystourethrogram (vcug), kidney ultrasound, dimercaptosuccinic acid(dmsa) renal scan, and urine culture. exclusion criteria: * excluded cases were patients who had vur grade 1 and grade 5, no complete follow-up work ups, concomitant neurogenic bladder, anatomical malformation of the urinary tract (obstruction, complete duplicated pelvocaliceal system), previous surgical or endoscopic procedures, and suspected or confirmed dysfunctional voiding by clinical findings or abnormal results (irregular bladder wall, diverticulum) on vcug or urodynamic study.

Keywords: vesicoureteral reflux (vur) complicated urinary tract infection vantris polyacrylate polyalcohol copolymer